Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

519 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.
Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M, Bedossa P, Betsou F, Boursier J, Brosnan MJ, Burt A, Cobbold J, Cortez-Pinto H, Day CP, Dufour JF, Ekstedt M, Francque S, Harrison S, Miele L, Nasr P, Papatheodoridis G, Petta S, Tiniakos D, Torstenson R, Valenti L, Holleboom AG, Yki-Jarvinen H, Geier A, Romero-Gomez M, Ratziu V, Bugianesi E, Schattenberg JM, Anstee QM; LITMUS Consortium. Hardy T, et al. Among authors: bedossa p. Contemp Clin Trials. 2020 Nov;98:106175. doi: 10.1016/j.cct.2020.106175. Epub 2020 Oct 9. Contemp Clin Trials. 2020. PMID: 33045403 Free article.
A comparison of fibrosis progression in chronic liver diseases.
Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P; PANFIBROSIS Group. Poynard T, et al. Among authors: bedossa p. J Hepatol. 2003 Mar;38(3):257-65. doi: 10.1016/s0168-8278(02)00413-0. J Hepatol. 2003. PMID: 12586290
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients.
Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, Iannelli A, Gugenheim J, Bedossa P, Francque S, Le Marchand-Brustel Y, Clement K, Van Gaal L, Sørensen TIA, Jess T. Zimmermann E, et al. Among authors: bedossa p. J Hepatol. 2011 Sep;55(3):660-665. doi: 10.1016/j.jhep.2010.12.017. Epub 2011 Jan 14. J Hepatol. 2011. PMID: 21238518
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
Poynard T, Lassailly G, Diaz E, Clement K, Caïazzo R, Tordjman J, Munteanu M, Perazzo H, Demol B, Callafe R, Pattou F, Charlotte F, Bedossa P, Mathurin P, Ratziu V; FLIP consortium. Poynard T, et al. Among authors: bedossa p. PLoS One. 2012;7(3):e30325. doi: 10.1371/journal.pone.0030325. Epub 2012 Mar 14. PLoS One. 2012. PMID: 22431959 Free PMC article.
Pathology of the liver sinusoids.
Brunt EM, Gouw AS, Hubscher SG, Tiniakos DG, Bedossa P, Burt AD, Callea F, Clouston AD, Dienes HP, Goodman ZD, Roberts EA, Roskams T, Terracciano L, Torbenson MS, Wanless IR. Brunt EM, et al. Among authors: bedossa p. Histopathology. 2014 Jun;64(7):907-20. doi: 10.1111/his.12364. Epub 2014 Mar 8. Histopathology. 2014. PMID: 24393125 Review.
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.
Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Lédinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K. Ratziu V, et al. Among authors: bedossa p. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5. doi: 10.1016/j.cgh.2014.01.040. Epub 2014 Feb 12. Clin Gastroenterol Hepatol. 2014. PMID: 24530600 Clinical Trial.
Well-differentiated hepatocellular neoplasm of uncertain malignant potential--reply.
Bedossa P, Burt AD, Brunt E, Callea F, Clouston AD, Dienes HP, Goodman ZD, Gouw AS, Hubscher SG, Roberts EA, Roskams T, Terracciano L, Tiniakos DG, Torbenson MS, Wanless IR. Bedossa P, et al. Hum Pathol. 2015 Apr;46(4):635-6. doi: 10.1016/j.humpath.2014.10.030. Epub 2014 Dec 31. Hum Pathol. 2015. PMID: 25732109 No abstract available.
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group. Ratziu V, et al. Among authors: bedossa p. Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11. Gastroenterology. 2016. PMID: 26874076 Free article. Clinical Trial.
519 results